Royce & Associates LP increased its stake in shares of Standard BioTools Inc. (NASDAQ:LAB - Free Report) by 37.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,000,503 shares of the company's stock after buying an additional 545,000 shares during the quarter. Royce & Associates LP owned 0.53% of Standard BioTools worth $2,161,000 at the end of the most recent quarter.
Several other institutional investors have also bought and sold shares of LAB. Two Sigma Securities LLC bought a new position in shares of Standard BioTools during the 4th quarter worth $30,000. Aquatic Capital Management LLC purchased a new stake in shares of Standard BioTools in the 4th quarter valued at about $45,000. CWM LLC raised its holdings in shares of Standard BioTools by 101.8% in the 1st quarter. CWM LLC now owns 29,705 shares of the company's stock valued at $32,000 after acquiring an additional 14,984 shares in the last quarter. Teacher Retirement System of Texas purchased a new position in shares of Standard BioTools during the 1st quarter valued at about $35,000. Finally, KLP Kapitalforvaltning AS purchased a new position in shares of Standard BioTools during the 4th quarter valued at about $70,000. Institutional investors own 53.74% of the company's stock.
Standard BioTools Trading Down 1.9%
Shares of LAB stock traded down $0.03 during trading hours on Friday, reaching $1.31. The company's stock had a trading volume of 823,392 shares, compared to its average volume of 1,798,777. The stock has a market capitalization of $495.67 million, a P/E ratio of -3.73 and a beta of 1.54. Standard BioTools Inc. has a one year low of $0.92 and a one year high of $2.32. The firm's fifty day simple moving average is $1.19 and its 200 day simple moving average is $1.24.
Analyst Upgrades and Downgrades
Separately, TD Cowen raised Standard BioTools to a "strong-buy" rating in a research note on Thursday, July 17th.
View Our Latest Analysis on LAB
Standard BioTools Company Profile
(
Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Featured Stories
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
